Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial

BACKGROUND. The RV144 ALVAC-HIV prime, AIDSVAX B/E boost afforded 60% efficacy against human immunodeficiency virus (HIV) acquisition at 1 year, waning to 31.2% after 3.5 years. We hypothesized that additional vaccinations might augment immune correlates of protection. METHODS. In a randomized place...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Infect Dis
Main Authors: Rerks-Ngarm, Supachai, Pitisuttithum, Punnee, Excler, Jean-Louis, Nitayaphan, Sorachai, Kaewkungwal, Jaranit, Premsri, Nakorn, Kunasol, Prayura, Karasavvas, Nicos, Schuetz, Alexandra, Ngauy, Viseth, Sinangil, Faruk, Dawson, Peter, deCamp, Allan C., Phogat, Sanjay, Garunathan, Sanjay, Tartaglia, James, DiazGranados, Carlos, Ratto-Kim, Silvia, Pegu, Poonam, Eller, Michael, Karnasuta, Chitraporn, Montefiori, David C., Sawant, Sheetal, Vandergrift, Nathan, Wills, Saintedym, Tomaras, Georgia D., Robb, Merlin L., Michael, Nelson L., Kim, Jerome H., Vasan, Sandhya, O’Connell, Robert J.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Major Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5853427/
https://ncbi.nlm.nih.gov/pubmed/28329190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jix099
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados